Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk

26 Oct 2022

Abstract excerpt

Lesniak RK, Nichols RJ

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments
Share to Plant Gene Expression Analysis

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 36388213
DOI: 10.3389/fneur.2022.1016040

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased riskPMID 36388213Read ↗

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s DiseaseSemantic proximity Read ↗

Modifiers of LRRK2 parkinsonism: new therapeutic targets.Semantic proximity Read ↗

A step forward for LRRK2 inhibitors in Parkinson's disease.Semantic proximity Read ↗

The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

LRRK2 inhibitor progresses for Parkinson disease.Semantic proximity Read ↗

LRRK2-targeted Parkinson disease drug advances into phase IIISemantic proximity Read ↗

Genetics of Parkinson's disease: LRRK2 on the rise.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

LRRK2 in Parkinson disease: challenges of clinical trialsSemantic proximity Read ↗

Parkinson's Disease: The LRRK2-G2019S mutation: opening a novel era in Parkinson's disease geneticsSemantic proximity Read ↗

Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.